Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-04-13

FDA Approved: NULOJIX — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

FDA approved a supplemental application for NULOJIX (belatacept) filed by E.R. Squibb & Sons, L.L.C. to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nulojix (belatacept)

Snippet

SUPPL AP for NULOJIX (BELATACEPT)